Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
RF/CCP negative, +hand synovitis on exam
Related Questions
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
What is the maximum dose of leucovorin that you use with methotrexate?
How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?
How would you manage a patient with RA with newly diagnosed T-LGLL who was previously treated with Enbrel and is now flaring off Enbrel while on low dose methotrexate?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
How do you approach management of RA in patients who have developed anti-drug antibodies to infliximab, especially if use of methotrexate is contraindicated and patients have tried and failed several other biologics?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?